Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy plus radiation for early lung cancer: trial halted early

NCT ID NCT03924869

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not have surgery. Participants received either SBRT plus pembrolizumab or SBRT plus a placebo. The trial was terminated early, so final results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda)
What this could lead to
If successful, this combination could improve the chance of keeping early-stage lung cancer from coming back after radiation.
What could go wrong
The trial was terminated early, so results may be incomplete. Adding immunotherapy to radiation can cause more side effects like lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

448 people

The number who actually took part.

Started

Jun 2019

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has previously untreated non-small cell lung cancer (NSCLC) diagnosed by histology or cytology and confirmed as Stage I or II (T1 to limited T3, N0, M0) NSCLC (American Joint Committee on Cancer, AJCC) by chest computed tomography (CT) and positron emission tomography (PET) scan. Participants with pericardium invasion, \>2 nodules or 2 nodules that cannot be treated in one field (\>2 cm apart and/or total planned target volume \[PTV\] \>163 cc) and diaphragm elevation suggestive of phrenic nerve invasion are excluded * Cannot undergo thoracic surgery due to existing medical illness(es) as determined by the site's multi-disciplinary tumor board. Medically operable participants who decide to treat with stereotactic body radiotherapy (SBRT) as definitive therapy rather than surgery are also eligible, if patient's unwillingness to undergo surgical resection is clearly documented * Has a Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Is able to receive SBRT and does not have an ultra-centrally located tumor * Has adequate organ function within 7 days prior to the start of study treatment * A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: a) not a women of childbearing potential (WOCBP) OR b) A WOCBP and uses contraceptive method that is highly effective (with a failure rate of \<1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 120 days after the last dose of pembrolizumab/placebo and 180 days after the last radiotherapy dose * Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of radiotherapy: refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent or must agree to use contraception per study protocol, unless confirmed to be azoospermic * Has a radiation therapy plan approved by the central radiation therapy quality assurance vendor Exclusion Criteria: * Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen 4 \[CTLA-4\], tumor necrosis factor receptor superfamily member 4 \[OX-40\], tumor necrosis factor receptor superfamily member 9 \[CD137\]) * Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or breast * Has received a live vaccine within 30 days prior to the first dose of study intervention * Has received an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention administration * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. A prior NSCLC that occurred and was treated curatively at least 2 years prior to the date of the current diagnosis would be considered a separate primary lung cancer, and therefore an additional malignancy. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast c carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. * Has a known hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis * Has a known history of Hepatitis B or known active Hepatitis C virus infection * Has an active autoimmune disease that has required systemic treatment in past 2 years, except replacement therapy * Has an active infection requiring systemic therapy * Has a known history of human immunodeficiency virus (HIV) infection * Has a known history of active tuberculosis (TB; Bacillus tuberculosis) * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab/placebo and 180 days after the last radiotherapy dose * Have not adequately recovered from major surgery or have ongoing surgical complications * Has had an allogenic tissue/solid organ transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • A.C. Camargo Cancer Center ( Site 0312)

    São Paulo, 01509-900, Brazil

  • A.O. Universitaria Careggi ( Site 1301)

    Florence, 50134, Italy

  • A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 1114)

    Paris, 75877, France

  • Aichi Cancer Center Hospital ( Site 2804)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Alaska Oncology and Hematology ( Site 3063)

    Anchorage, Alaska, 99508, United States

  • Allegheny General Hospital ( Site 3028)

    Pittsburgh, Pennsylvania, 15212, United States

  • Amethyst Radiotherapy Center-Oncologie Medicala ( Site 3201)

    Florești, Cluj, 407280, Romania

  • Auckland City Hospital ( Site 2900)

    Grafton, Auckland, 1023, New Zealand

  • Austin Health ( Site 2501)

    Melbourne, Victoria, 3084, Australia

  • Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1309)

    Roma, 00185, Italy

  • Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 2311)

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Banner MD Anderson Cancer Center ( Site 3029)

    Gilbert, Arizona, 85234, United States

  • Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2105)

    Adana, 01250, Turkey (Türkiye)

  • CARTI Cancer Center ( Site 3045)

    Little Rock, Arkansas, 72205, United States

  • CEMIC ( Site 0201)

    Buenos Aires, C1431, Argentina

  • CHU Poitiers ( Site 1109)

    Poitiers, Ain, 86021, France

  • CHU de Brest -Site Hopital Morvan ( Site 1100)

    Brest, Finistere, 29200, France

  • CHU de Rouen ( Site 1113)

    Rouen, Seine-Maritime, 76000, France

  • CHUS - Hopital Fleurimont ( Site 0111)

    Sherbrooke, Quebec, J1H 5N4, Canada

  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0110)

    Montreal, Quebec, H1T 2M4, Canada

  • CRU Hungary KFT ( Site 2309)

    Miskolc, Borsod-Abauj Zemplen county, 3529, Hungary

  • Cancer Care Northwest ( Site 0063)

    Spokane Valley, Washington, 99216, United States

  • Centrum Onkologii im. prof. Franciszka ukaszczyka-Ambulatorium Chemioterapii ( Site 2407)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Charite Universitaetsmedizin Berlin ( Site 1207)

    Berlin, 13353, Germany

  • Chelyabinsk Regional Clinical Oncology Dispensary ( Site 2014)

    Chelyabinsk, Chelyabinsk Oblast, 454087, Russia

  • Chiba University Hospital ( Site 2806)

    Chiba, 260-8677, Japan

  • Chungbuk National University Hospital ( Site 2605)

    Cheongju-si, North Chungcheong, 28644, South Korea

  • Clatterbridge Cancer Center NHS FT ( Site 1800)

    Liverpool, England, L7 8YA, United Kingdom

  • Clínica de Oncologia Reichow ( Site 0319)

    Blumenau, Santa Catarina, 89010-340, Brazil

  • Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 3060)

    Springfield, Missouri, 65807, United States

  • Darlington Memorial Hospital NHS Trust ( Site 1810)

    Darlington, DLX 6HX, United Kingdom

  • Debreceni Egyetem Klinikai Kozpont ( Site 2301)

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 2101)

    Ankara, 06200, Turkey (Türkiye)

  • Erciyes University Medical Faculty ( Site 2109)

    Kayseri, 38030, Turkey (Türkiye)

  • Evangelisches Krankenhaus Hamm gGmbH ( Site 1205)

    Hamm, North Rhine-Westphalia, 59063, Germany

  • Farkasgyepui Tudogyogyintezet ( Site 2313)

    Farkasgyepű, Veszprém megye, 8582, Hungary

  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz ( Site 2312)

    Székesfehérvár, Fejér, 8000, Hungary

  • Fox Chase Cancer Center ( Site 0051)

    Philadelphia, Pennsylvania, 19111, United States

  • Franciscan Health Indianapolis ( Site 0024)

    Indianapolis, Indiana, 46237, United States

  • GUZ Lipetsk Regional Oncology Dispensary ( Site 2010)

    Lipetsk, Lipetsk Oblast, 398005, Russia

  • GenesisCare North Shore ( Site 2508)

    St Leonards, New South Wales, 2065, Australia

  • Goshen Center for Cancer Care ( Site 0022)

    Goshen, Indiana, 46526, United States

  • Guy s and St Thomas Hospital NHS Foundation Trust ( Site 1808)

    London, London, City of, SE1 9RT, United Kingdom

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2116)

    Istanbul, 34722, Turkey (Türkiye)

  • H. Lee Moffitt Cancer Center and Research Institute ( Site 0016)

    Tampa, Florida, 33612, United States

  • Hacettepe University Medical Faculty ( Site 2100)

    Ankara, 06100, Turkey (Türkiye)

  • Health Sciences North Research Institute ( Site 0107)

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • Helse Bergen HF Haukeland Universitetssykehus ( Site 1502)

    Bergen, Vestfold, 5021, Norway

  • Hematology-Oncology Associates of CNY ( Site 3055)

    East Syracuse, New York, 13057, United States

  • Hiroshima University Hospital ( Site 2810)

    Hiroshima, 734-8551, Japan

  • Hopital Cochin ( Site 1107)

    Paris, 75014, France

  • Hopital Sud du Amiens ( Site 1115)

    Amiens, Somme, 80054, France

  • Hopitaux Universitaires de Geneve HUG ( Site 1706)

    Geneva, Canton of Geneva, 1211, Switzerland

  • Hospital Aleman ( Site 0200)

    Buenos Aires, C1118AAT, Argentina

  • Hospital Britanico de Buenos Aires ( Site 0204)

    Buenos Aires, Buenos Aires F.D., C1280AEB, Argentina

  • Hospital General Universitari Vall d Hebron ( Site 1602)

    Barcelona, 08035, Spain

  • Hospital General Universitario Gregorio Maranon ( Site 1604)

    Madrid, 28009, Spain

  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0206)

    ABB, Buenos Aires F.D., C1199ABB, Argentina

  • Hospital Paulistano - Amil Clinical Research ( Site 0316)

    São Paulo, 01321-001, Brazil

  • Hospital Provincial del Centenario ( Site 0205)

    Rosario, Santa Fe Province, S2002KDS, Argentina

  • Hospital Universitario La Fe ( Site 1603)

    Valencia, Valenciana, Comunitat, 46206, Spain

  • Hospital Universitario Quiron Madrid ( Site 1601)

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Hospital e Maternidade Celso Pierro ( Site 0313)

    Campinas, São Paulo, 13060-904, Brazil

  • I.E.U. Medical Point Hastanesi ( Site 2115)

    Izmir, 35520, Turkey (Türkiye)

  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0208)

    Buenos Aires, 1012, Argentina

  • Icon Cancer Centre Hobart ( Site 2507)

    Hobart, Tasmania, 7000, Australia

  • Infirmary Cancer Care ( Site 3044)

    Mobile, Alabama, 36607, United States

  • Institut Bergonie ( Site 1102)

    Bordeaux, Gironde, 33076, France

  • Institut Curie ( Site 1112)

    Paris, 75005, France

  • Institut Regional du Cancer de Montpellier - ICM ( Site 1108)

    Montpellier, Herault, 34298, France

  • Instituto Medico Especializado Alexander Fleming ( Site 0203)

    Buenos Aires, C1426ANZ, Argentina

  • Instituto Nacional Do Cancer Jose Alencar Gomes Da Silva ( Site 0305)

    Rio de Janeiro, 20231-050, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0300)

    São Paulo, 01246-000, Brazil

  • Institutul Oncologic-Oncologie Medicala ( Site 3202)

    Cluj-Napoca, 400015, Romania

  • Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0318)

    Porto Alegre, Rio Grande do Sul, 90050-170, Brazil

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 3036)

    Hackensack, New Jersey, 07601, United States

  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 2310)

    Szolnok, Jász-Nagykun-Szolnok, 5004, Hungary

  • Kansai Medical University Hospital ( Site 2808)

    Hirakata, Osaka, 573-1191, Japan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 3304)

    Kaohsiung City, 807, Taiwan

  • Kartal Training and Research Hospital ( Site 2102)

    Istanbul, 34890, Turkey (Türkiye)

  • Keppler Universitatsklinikum ( Site 0806)

    Linz, Upper Austria, 4021, Austria

  • Kingston Health Sciences Centre ( Site 0100)

    Kingston, Ontario, K7L 2V7, Canada

  • Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1208)

    Esslingen am Neckar, Baden-Wurttemberg, 73730, Germany

  • Kobe Minimally Invasive Cancer Center ( Site 2811)

    Kobe, Hyōgo, 650-0046, Japan

  • Kurume University Hospital ( Site 2815)

    Kurume, Fukuoka, 830-0011, Japan

  • Kyiv City Clinical Oncology Centre ( Site 2200)

    Kyiv, 03115, Ukraine

  • Lancashire Teaching Hospitals NHS Foundation Trust ( Site 1809)

    Preston, Lancashire, PR2 9HT, United Kingdom

  • Landeskrankenhaus - Universitatsklinikum Graz ( Site 0804)

    Graz, Styria, 8036, Austria

  • Lankenau Medical Center ( Site 3041)

    Wynnewood, Pennsylvania, 19096, United States

  • Lehigh Valley Hospital- Cedar Crest ( Site 3005)

    Allentown, Pennsylvania, 18103, United States

  • Leicester Royal Infirmary ( Site 1811)

    Leicester, Leicestershire, LE1 5WW, United Kingdom

  • Mass General / North Shore Center for Outpatient Care ( Site 3040)

    Danvers, Massachusetts, 01923, United States

  • Massachusetts General Hospital-Cancer Center Protocol Office ( Site 3007)

    Boston, Massachusetts, 02114, United States

  • McGill University Health Centre ( Site 0113)

    Montreal, Quebec, H4A 3J1, Canada

  • Meander Medisch Centrum-Studie Team Oncologie ( Site 1403)

    Amersfoort, Utrecht, 3813 TZ, Netherlands

  • Medical Center Asklepion LLC ( Site 2208)

    Khodosovka, Kyivska Oblast, 08173, Ukraine

  • Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2205)

    Kapitanivka Village, Kyivska Oblast, 08111, Ukraine

  • Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2203)

    Kyiv, Kyivska Oblast, 03126, Ukraine

  • Medical center Medikal Plaza of Ecodnipro LLC ( Site 2207)

    Dnipro, Dnipropetrovsk Oblast, 49055, Ukraine

  • Medical institute named after Berezin Sergey ( Site 2009)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Mid Florida Hematology and Oncology Center ( Site 0067)

    Orange City, Florida, 32763, United States

  • Moncton Hospital - Horizon Health Network ( Site 0105)

    Moncton, New Brunswick, E1C 6Z8, Canada

  • Mount Sinai Hospital ( Site 0046)

    New York, New York, 10029, United States

  • Mount Vernon Hospital ( Site 1803)

    Northwood, HA6 2RN, United Kingdom

  • Mountain States Health Alliance ( Site 3054)

    Johnson City, Tennessee, 37604, United States

  • N.N.Blokhin Russian Cancer Research center ( Site 2013)

    Moscow, Moscow, 115478, Russia

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2403)

    Gliwice, Silesian Voivodeship, 44-101, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center ( Site 2604)

    Goyang-si, Kyonggi-do, 10408, South Korea

  • National Cancer Center Hospital East ( Site 2800)

    Kashiwa, Chiba, 2778577, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 2816)

    Fukuoka, 811-1395, Japan

  • National Jewish Health ( Site 0010)

    Denver, Colorado, 80206, United States

  • Niigata Cancer Center Hospital ( Site 2801)

    Niigata, 951-8566, Japan

  • Norfolk and Norwich University Foundation NHS Trust ( Site 1805)

    Norwich, Norfolk, NR47UY, United Kingdom

  • Orszagos Koranyi Pulmonologiai Intezet ( Site 2304)

    Budapest, 1121, Hungary

  • Orszagos Koranyi Pulmonologiai Intezet ( Site 2306)

    Budapest, 1121, Hungary

  • Orszagos Onkologiai Intezet ( Site 2308)

    Budapest, 1122, Hungary

  • Osaka International Cancer Institute ( Site 2812)

    Osaka, 541-8567, Japan

  • Osaka Medical and Pharmaceutical University Hospital ( Site 2813)

    Takatsuki, Osaka, 5698686, Japan

  • Oslo Universitetssykehus HF Ulleval Sykehus ( Site 1500)

    Oslo, 0450, Norway

  • Ospedale Santissima Annunziata ( Site 1303)

    Chieti, 66100, Italy

  • Oxford University Hospitals NHS Foundation Trust ( Site 1812)

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

  • Penn State University Milton S. Hershey Medical Center ( Site 0064)

    Hershey, Pennsylvania, 17033, United States

  • Petz Aladar Megyei Oktato Korhaz ( Site 2305)

    Győr, Győr-Moson-Sopron, 9024, Hungary

  • Pius Hospital Oldenburg ( Site 1202)

    Oldenburg, Lower Saxony, 26121, Germany

  • Policlinico Agostino Gemelli ( Site 1302)

    Roma, 00168, Italy

  • Policlinico di Modena ( Site 1306)

    Modena, 41124, Italy

  • Port Macquarie Base Hospital ( Site 2500)

    Port Macquarie, New South Wales, 2444, Australia

  • Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 2314)

    Pécs, Baranya, 7624, Hungary

  • Regional Centre of Oncology-Thoracic organs ( Site 2202)

    Kharkiv, Kharkiv Oblast, 61070, Ukraine

  • Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 2001)

    Kazan', Tatarstan, Respublika, 420029, Russia

  • Royal Brisbane and Women s Hospital ( Site 2502)

    Herston, Queensland, 4029, Australia

  • Royal Free London NHS Foundation Trust ( Site 1813)

    London, Camden, NW3 2QG, United Kingdom

  • Russian Scientific Center of Roentgenoradiology ( Site 2011)

    Moscow, Moscow, 117997, Russia

  • Rutgers Cancer Institute of New Jersey ( Site 0043)

    New Brunswick, New Jersey, 08903-2681, United States

  • SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2404)

    Olsztyn, Warmian-Masurian Voivodeship, 10-228, Poland

  • Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 2114)

    Sakarya, 54290, Turkey (Türkiye)

  • Samsung Medical Center ( Site 2603)

    Seoul, 06351, South Korea

  • Sanatorio Parque ( Site 0207)

    Rosario, Santa Fe Province, S2000DSV, Argentina

  • Sanford Bemidji ( Site 0080)

    Bemidji, Minnesota, 56601, United States

  • Sanford Cancer Center Oncology Clinic ( Site 0053)

    Sioux Falls, South Dakota, 57104, United States

  • Sanford Health Roger Maris Cancer Center ( Site 0079)

    Fargo, North Dakota, 58102, United States

  • Sault Area Hospital ( Site 0101)

    Sault Ste. Marie, Ontario, P6B 0A8, Canada

  • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2000)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Semmelweis University ( Site 2303)

    Budapest, 1085, Hungary

  • Sendai Kousei Hospital ( Site 2814)

    Sendai, Miyagi, 980-0873, Japan

  • Seoul National University Hospital ( Site 2600)

    Seoul, 03080, South Korea

  • Showa University Hospital ( Site 2805)

    Tokyo, 142-8666, Japan

  • Sinai Hospital of Baltimore ( Site 3011)

    Baltimore, Maryland, 21215, United States

  • Social Medical Center - Otto Wagner Hospital ( Site 0801)

    Vienna, State of Vienna, 1145, Austria

  • Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 2307)

    Kaposvár, Somogy County, 7400, Hungary

  • St Olavs Hospital ( Site 1504)

    Trondheim, Sor-Trondelag, 7030, Norway

  • St. Luke's University Health Network ( Site 3006)

    Bethlehem, Pennsylvania, 18015, United States

  • St. Vincent Healthcare Frontier Cancer Center ( Site 3012)

    Billings, Montana, 59102, United States

  • Sverdlovsk Regional Oncology Hospital ( Site 2012)

    Yekaterinburg, Sverdlovsk Oblast, 620036, Russia

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 2400)

    Krakow, Lesser Poland Voivodeship, 31-826, Poland

  • Taipei Medical University Hospital ( Site 3303)

    Taipei, 110301, Taiwan

  • Taipei Veterans General Hospital ( Site 3301)

    Taipei, 11217, Taiwan

  • Tergooiziekenhuizen, locatie Hilversum-Oncology ( Site 1407)

    Hilversum, North Holland, 1213 XZ, Netherlands

  • The Cancer Institute Hospital of JFCR ( Site 2803)

    Tokyo, 135-8550, Japan

  • The Catholic University of Korea St. Vincent s Hospital ( Site 2606)

    Gyeonggi-do, Kyonggi-do, 16247, South Korea

  • The Ottawa Hospital ( Site 0104)

    Ottawa, Ontario, K1H 8L6, Canada

  • Tokyo Metropolitan Komagome Hospital ( Site 2802)

    Tokyo, 113-8677, Japan

  • Tri-Service General Hospital ( Site 3300)

    Taipei City, Taipei, 114, Taiwan

  • Trillium Health Partners - Credit Valley Hospital ( Site 0102)

    Mississauga, Ontario, L5M 2N1, Canada

  • Törökbálinti Tüdőgyógyintézet ( Site 2302)

    Törökbálint, Pest County, 2045, Hungary

  • UKGM Gießen/Marburg-Medical Clinic V ( Site 1210)

    Giessen, Hesse, 35392, Germany

  • USC Norris Comprehensive Cancer Center ( Site 0007)

    Los Angeles, California, 90033, United States

  • Ukrainian Center of Tomotherapy ( Site 2206)

    Kropyvnitskiy, Kirovohrad Oblast, 25011, Ukraine

  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0301)

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Universitaetsklinikum Erlangen ( Site 1209)

    Erlangen, Bavaria, 91054, Germany

  • Universitaetsklinikum Essen ( Site 1201)

    Essen, North Rhine-Westphalia, 45147, Germany

  • Universitaetsklinikum Heidelberg. ( Site 1204)

    Heidelberg, Baden-Wurttemberg, 69126, Germany

  • Universitaetsspital Zuerich ( Site 1700)

    Zurich, Canton of Zurich, 8091, Switzerland

  • Universitatsklinik LKH Innsbruck ( Site 0802)

    Innsbruck, Tyrol, 6020, Austria

  • University College London Hospital NHS Foundation Trust ( Site 1806)

    London, London, City of, NW1 2BU, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust ( Site 1802)

    Bristol, Bristol, City of, BS2 8ED, United Kingdom

  • University of Alabama ( Site 0099)

    Birmingham, Alabama, 35233, United States

  • University of Kentucky School of Medicine & Hospitals ( Site 0026)

    Lexington, Kentucky, 40536, United States

  • University of Massachusetts ( Site 0029)

    Worcester, Massachusetts, 01655, United States

  • University of Minnesota ( Site 0069)

    Minneapolis, Minnesota, 55455, United States

  • University of Missouri Hospital ( Site 3058)

    Columbia, Missouri, 65212, United States

  • University of Tennessee Medical Center Knoxville ( Site 3010)

    Knoxville, Tennessee, 37920, United States

  • University of Tsukuba Hospital ( Site 2809)

    Tsukuba, Ibaraki, 305-8576, Japan

  • University of Yamanashi Hospital ( Site 2807)

    Chūō, Yamanashi, 409-3898, Japan

  • Vanderbilt University Medical Center ( Site 0075)

    Nashville, Tennessee, 37232, United States

  • Veterans Affairs Palo Alto Health Care System ( Site 3039)

    Palo Alto, California, 94304, United States

  • Westchester Medical Center ( Site 3057)

    Valhalla, New York, 10595, United States

  • Weston Park Hospital ( Site 1801)

    Sheffield, Derbyshire, S10 2SJ, United Kingdom

  • White Plains Hospital ( Site 3014)

    White Plains, New York, 10601, United States

  • William E. Kahlert Regional Cancer Center ( Site 3031)

    Westminster, Maryland, 21157, United States

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii ( Site 2402)

    Lodz, Łódź Voivodeship, 93-513, Poland

  • Yale University ( Site 0011)

    New Haven, Connecticut, 06510, United States

  • Ziekenhuis Rijnstate ( Site 1405)

    Arnhem, Gelderland, 6815 AD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.